|1.||Huizing, Marjan: 5 articles (09/2015 - 11/2005)|
|2.||Gahl, William A: 5 articles (09/2015 - 11/2005)|
|3.||Clement, Lionel C: 3 articles (01/2014 - 01/2011)|
|4.||Macé, Camille: 3 articles (01/2014 - 01/2011)|
|5.||Chugh, Sumant S: 3 articles (01/2014 - 01/2011)|
|6.||Ciccone, Carla: 3 articles (08/2013 - 11/2005)|
|7.||Carrillo-Carrasco, Nuria: 2 articles (09/2015 - 04/2015)|
|8.||Nishino, Ichizo: 2 articles (04/2015 - 01/2012)|
|9.||Yardeni, Tal: 2 articles (03/2014 - 08/2013)|
|10.||Aich, Udayanath: 2 articles (08/2011 - 12/2008)|
|1.||Muscular Diseases (Myopathy)
09/01/2015 - "Its precursor, N-acetylmannosamine (ManNAc), is being investigated as a potential treatment for GNE myopathy. "
04/01/2015 - "Based upon the pathophysiology of the disease, recent clinical trials as well as early gene therapy trials have evaluated the use of sialic acid or N-acetylmannosamine (a precursor of sialic acid) in patients with GNE myopathy. "
03/01/2014 - "Treatment of GNE myopathy fibroblasts with N-acetylmannosamine (ManNAc), a sialic acid precursor downstream of GNE epimerase activity, ameliorated the increased total GSL concentrations. "
08/01/2013 - "However, upon treatment of these mice with N-acetylmannosamine (ManNAc, a Gne substrate, sialic acid precursor, and proposed therapy for GNE myopathy), Gne transcript expression, in particular mGne2, increased significantly, likely resulting in increased Gne enzymatic activities. "
01/20/2012 - "Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy."
01/01/2014 - "Oral treatment with low doses of N-acetyl-D-mannosamine, a naturally occurring precursor of sialic acid, improves sialylation of Angptl4 in vivo, and reduces proteinuria by over 40%. "
02/01/2012 - "At least some of this ability of ANGPTL4 to induce proteinuria is linked to a deficiency of sialic acid residues because oral supplementation with sialic acid precursor N-acetyl-d-mannosamine improves sialylation of podocyte-secreted ANGPTL4 and significantly decreases proteinuria. "
06/01/2007 - "Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine."
08/01/1986 - "To investigate the effect of TRH on TSH sulfation and sialylation, thyrotropic tumor minces and hypothyroid pituitaries were incubated with [35S]sulfate or [3H]N-acetylmannosamine, with or without 10(-7) M TRH; labeling was then normalized in each case to incorporation of [3H]mannose, a marker of the inner core sugars. "
08/01/1986 - "To determine whether sulfate and/or sialic acid are present on secreted mouse TSH, thyrotropic tumor minces and hypothyroid pituitaries were incubated with [3H]methionine and [35S]sulfate, or [35S]methionine and [3H]N-acetylmannosamine. "
12/25/2008 - "Per-butanoylated N-acetyl-D-mannosamine (Bu(4)ManNAc), a SCFA-hexosamine cancer drug candidate with activity manifest through intact n-butyrate-carbohydrate linkages, reduced the invasion of metastatic MDA-MB-231 breast cancer cells unlike per-butanoylated-D-mannose (Bu(5)Man), a clinically tested compound that did not alter cell mobility. "
02/20/2007 - "Alkynyl sugar monomers, based on fucose (Fuc) and N-acetylmannosamine (ManNAc), were incorporated into fucosylated and sialylated glycans in several cancer cell lines, allowing for cell surface and intracellular visualization of glycoconjugates, as well as, observation of alkyne-bearing glycoproteins. "
|4.||Sialic Acid Storage Disease (Salla Disease)
05/09/1986 - "Fibroblast granular fractions of patients with Salla disease exhibited negligible egress of sialic acid, whether endogenous or derived from N-acetylmannosamine exposure. "
03/22/1979 - "A new metabolite, namely 2-acetamidoglucal, has been found in the urine of a patient with sialuria in addition to the metabolites N-acetylneuraminic acid, N-acetylmannosamine, N-acetylglucosamine and 2-deoxy-2,3-dehydro-N-acetylneuraminic acid reported earlier. "
|5.||Acute Erythroblastic Leukemia (Erythroleukemia)
07/01/1983 - "The 1,3,6-tri-O-acetyl and 1,3,6-tri-O-acetyl-4-O-mesyl analogues of N-acetyl-D-mannosamine and the corresponding N-trifluoroacetyl derivative have been synthesized, and their effects on the proliferation of Friend erythroleukemia cells in culture have been evaluated. "
07/14/1983 - "Modification of sialic acid metabolism of murine erythroleukemia cells by analogs of N-acetylmannosamine."
07/14/1983 - "Two analogs of N-acetylmannosamine, 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-D-mannopyranose (Ac4-NAcMan) and the 2-trifluoroacetamido derivative (AC4F3-NAcMan), were synthesized as potential inhibitors of the formation of sialic acid-containing glycoconjugates and were examined for their ability to modify the incorporation of N-[3H]acetylamannosamine into cellular glycoconjugates of Friend murine erythroleukemia cells. "
|1.||N-Acetylneuraminic Acid (Sialic Acid)
|6.||Uridine Diphosphate (UDP)
|10.||Cytidine Monophosphate N-Acetylneuraminic Acid